News

According to FDA, the data provided by the company was insufficient regarding migrane indication, painmedicinenews.com reported. NuPathe conducted a Phase III trial testing the efficacy of the transdermal

The company’s anti-retroviral drug, Lamozid, has been pre-qualified and included in a list of about 255 drugs approved for the fund which develops and manufactures drugs against malaria,

Adasuve utilizes the company’s proprietary oral inhalation technology – Staccato system – which provides systemic delivery of a thermally-generated aerosol of loxapine. The MAA seeks approval for the

The new formulation contains oil in oral dispensing syringes for patient self-administration and is said to help patients use concentrated cannabis extracts to treat their ailments. According to

The products include Glucerna Hunger Smart shakes and bars, which comprise carbohydrate blend, carbsteady which includes both low glycemic and slowly-digestible carbohydrates that reduce blood sugar spikes. Glucerna

Following approval, the Quad will be the only once-daily, single-tablet regimen containing an integrase inhibitor. The submission of NDA was done on the back of positive data from

The therapeutic platform comprises a novel proprietary and IP-protected approach, which includes utilisation of a bacterial danger signal in combination with the patient’s tumour antigens to mobilise the

Study 101 evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, while Study 102 assessed multiple-dosing of PEGPH20 in combination with dexamethasone. The results

Rusnano is co-investing $25m in Bind and other $25m in Selecta. Bind and Selecta intend to strengthen their US-based operations by setting up subsidiaries in Russia to develop